Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

Matthias Totzeck; Nicolas Aide; Johann Bauersachs; Jan Bucerius; Panagiotis Georgoulias; Ken Herrmann; Fabien Hyafil; Jolanta Kunikowska; Mark Lubberink; Carmela Nappi; Tienush Rassaf; Antti Saraste; Roberto Sciagra; Riemer H.J.A. Slart; Hein Verberne; Christoph Rischpler

doi:10.1007/s00259-022-05991-7

Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

Matthias Totzeck, Nicolas Aide, Johann Bauersachs, Jan Bucerius, Panagiotis Georgoulias, Ken Herrmann, Fabien Hyafil, Jolanta Kunikowska, Mark Lubberink, Carmela Nappi, Tienush Rassaf, Antti Saraste, Roberto Sciagra, Riemer H.J.A. Slart, Hein Verberne, Christoph Rischpler^*

^*Corresponding author for this work

Biomedical Photonic Imaging

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

89 Downloads (Pure)

Abstract

Abstract: Cardiotoxicity may present as (pulmonary) hypertension, acute and chronic coronary syndromes, venous thromboembolism, cardiomyopathies/heart failure, arrhythmia, valvular heart disease, peripheral arterial disease, and myocarditis. Many of these disease entities can be diagnosed by established cardiovascular diagnostic pathways. Nuclear medicine, however, has proven promising in the diagnosis of cardiomyopathies/heart failure, and peri- and myocarditis as well as arterial inflammation. This article first outlines the spectrum of cardiotoxic cancer therapies and the potential side effects. This will be complemented by the definition of cardiotoxicity using non-nuclear cardiovascular imaging (echocardiography, CMR) and biomarkers. Available nuclear imaging techniques are then presented and specific suggestions are made for their application and potential role in the diagnosis of cardiotoxicity.

Original language	English
Pages (from-to)	792-812
Journal	European journal of nuclear medicine and molecular imaging
Volume	50
DOIs	https://doi.org/10.1007/s00259-022-05991-7
Publication status	Published - Feb 2023

Keywords

Cancer therapy-related cardiotoxicity
Cardio-oncology
Chemotherapy
Immunotherapy
Nuclear medicine
PET
Radiotherapy
SPECT

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00259-022-05991-7Licence: CC BY

s00259-022-05991-7Final published version, 1.99 MBLicence: CC BY

Cite this

Totzeck, M., Aide, N., Bauersachs, J., Bucerius, J., Georgoulias, P., Herrmann, K., Hyafil, F., Kunikowska, J., Lubberink, M., Nappi, C., Rassaf, T., Saraste, A., Sciagra, R., Slart, R. H. J. A., Verberne, H., & Rischpler, C. (2023). Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM). European journal of nuclear medicine and molecular imaging, 50, 792-812. https://doi.org/10.1007/s00259-022-05991-7

@article{9faadb6a4c194c10ba46a41a16cd1e97,

title = "Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)",

abstract = "Abstract: Cardiotoxicity may present as (pulmonary) hypertension, acute and chronic coronary syndromes, venous thromboembolism, cardiomyopathies/heart failure, arrhythmia, valvular heart disease, peripheral arterial disease, and myocarditis. Many of these disease entities can be diagnosed by established cardiovascular diagnostic pathways. Nuclear medicine, however, has proven promising in the diagnosis of cardiomyopathies/heart failure, and peri- and myocarditis as well as arterial inflammation. This article first outlines the spectrum of cardiotoxic cancer therapies and the potential side effects. This will be complemented by the definition of cardiotoxicity using non-nuclear cardiovascular imaging (echocardiography, CMR) and biomarkers. Available nuclear imaging techniques are then presented and specific suggestions are made for their application and potential role in the diagnosis of cardiotoxicity.",

keywords = "Cancer therapy-related cardiotoxicity, Cardio-oncology, Chemotherapy, Immunotherapy, Nuclear medicine, PET, Radiotherapy, SPECT",

author = "Matthias Totzeck and Nicolas Aide and Johann Bauersachs and Jan Bucerius and Panagiotis Georgoulias and Ken Herrmann and Fabien Hyafil and Jolanta Kunikowska and Mark Lubberink and Carmela Nappi and Tienush Rassaf and Antti Saraste and Roberto Sciagra and Slart, {Riemer H.J.A.} and Hein Verberne and Christoph Rischpler",

note = "Publisher Copyright: {\textcopyright} 2022, The Author(s).",

year = "2023",

month = feb,

doi = "10.1007/s00259-022-05991-7",

language = "English",

volume = "50",

pages = "792--812",

journal = "European journal of nuclear medicine and molecular imaging",

issn = "1619-7070",

publisher = "Springer",

}

Totzeck, M, Aide, N, Bauersachs, J, Bucerius, J, Georgoulias, P, Herrmann, K, Hyafil, F, Kunikowska, J, Lubberink, M, Nappi, C, Rassaf, T, Saraste, A, Sciagra, R, Slart, RHJA, Verberne, H & Rischpler, C 2023, 'Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)', European journal of nuclear medicine and molecular imaging, vol. 50, pp. 792-812. https://doi.org/10.1007/s00259-022-05991-7

Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM). / Totzeck, Matthias; Aide, Nicolas; Bauersachs, Johann et al.
In: European journal of nuclear medicine and molecular imaging, Vol. 50, 02.2023, p. 792-812.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity

T2 - prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

AU - Totzeck, Matthias

AU - Aide, Nicolas

AU - Bauersachs, Johann

AU - Bucerius, Jan

AU - Georgoulias, Panagiotis

AU - Herrmann, Ken

AU - Hyafil, Fabien

AU - Kunikowska, Jolanta

AU - Lubberink, Mark

AU - Nappi, Carmela

AU - Rassaf, Tienush

AU - Saraste, Antti

AU - Sciagra, Roberto

AU - Slart, Riemer H.J.A.

AU - Verberne, Hein

AU - Rischpler, Christoph

PY - 2023/2

Y1 - 2023/2

N2 - Abstract: Cardiotoxicity may present as (pulmonary) hypertension, acute and chronic coronary syndromes, venous thromboembolism, cardiomyopathies/heart failure, arrhythmia, valvular heart disease, peripheral arterial disease, and myocarditis. Many of these disease entities can be diagnosed by established cardiovascular diagnostic pathways. Nuclear medicine, however, has proven promising in the diagnosis of cardiomyopathies/heart failure, and peri- and myocarditis as well as arterial inflammation. This article first outlines the spectrum of cardiotoxic cancer therapies and the potential side effects. This will be complemented by the definition of cardiotoxicity using non-nuclear cardiovascular imaging (echocardiography, CMR) and biomarkers. Available nuclear imaging techniques are then presented and specific suggestions are made for their application and potential role in the diagnosis of cardiotoxicity.

AB - Abstract: Cardiotoxicity may present as (pulmonary) hypertension, acute and chronic coronary syndromes, venous thromboembolism, cardiomyopathies/heart failure, arrhythmia, valvular heart disease, peripheral arterial disease, and myocarditis. Many of these disease entities can be diagnosed by established cardiovascular diagnostic pathways. Nuclear medicine, however, has proven promising in the diagnosis of cardiomyopathies/heart failure, and peri- and myocarditis as well as arterial inflammation. This article first outlines the spectrum of cardiotoxic cancer therapies and the potential side effects. This will be complemented by the definition of cardiotoxicity using non-nuclear cardiovascular imaging (echocardiography, CMR) and biomarkers. Available nuclear imaging techniques are then presented and specific suggestions are made for their application and potential role in the diagnosis of cardiotoxicity.

KW - Cancer therapy-related cardiotoxicity

KW - Cardio-oncology

KW - Chemotherapy

KW - Immunotherapy

KW - Nuclear medicine

KW - PET

KW - Radiotherapy

KW - SPECT

UR - http://www.scopus.com/inward/record.url?scp=85141413966&partnerID=8YFLogxK

U2 - 10.1007/s00259-022-05991-7

DO - 10.1007/s00259-022-05991-7

M3 - Article

C2 - 36334105

AN - SCOPUS:85141413966

SN - 1619-7070

VL - 50

SP - 792

EP - 812

JO - European journal of nuclear medicine and molecular imaging

JF - European journal of nuclear medicine and molecular imaging

ER -

Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this